Literature DB >> 11574412

Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.

S Nielsen1, N Møller, J S Christiansen, J O Jørgensen.   

Abstract

Stimulation of lipolysis and the induction of resistance to insulin's actions on glucose metabolism are well-recognized effects of growth hormone (GH). To evaluate whether these two features are causally linked, we studied the impact of pharmacologically induced antilipolysis in seven GH-deficient patients (mean [+/- SE] age 37 +/- 4 years). Each subject was studied under four different conditions: during continuation of GH replacement alone (A), after discontinuation of GH replacement for 2 days (B), after GH replacement and short-term coadministration of acipimox (250 mg, p.o., b.i.d., for 2 days) (C), and after administration of acipimox alone (D). At the end of each study, total and regional substrate metabolisms were assessed in the basal state and after a 3-h hyperinsulinemic/euglycemic clamp. Serum levels of free fatty acids (FFAs) were elevated with GH alone (A) and suppressed with acipimox (C and D). Basal rates of lipid oxidation were highest with GH alone (A), and suppressed by 50% with acipimox (B versus D, P < 0.01; A versus C, P < 0.05). Basal glucose oxidation rates were lowest with GH alone (A) and highest with acipimox (C and D) (P = 0.01). Insulin-stimulated rates of total glucose turnover were significantly lower with GH alone as compared with all other conditions (P = 0.004). Insulin sensitivity as assessed by the M value (rate of glucose infusion) was reduced with GH alone as compared with all other conditions (M value in mg. kg(-1). min(-1): GH alone [A], 2.55 +/- 0.64; discontinuation of GH [B], 4.01 +/- 0.70; GH plus acipimox [C], 3.96 +/- 1.34; acipimox alone [D], 4.96 +/- 0.91; P < 0.01). During pharmacological antilipolysis, GH did not significantly influence insulin sensitivity (C versus D; P = 0.19). From our results, we reached the following conclusions: 1) Our data strongly suggest that the insulin antagonistic actions of GH on glucose metabolism are causally linked to the concomitant activation of lipolysis. 2) In addition, GH may induce residual insulin resistance through non-FFA-dependent mechanisms. 3) The cellular and molecular mechanisms subserving the insulin antagonistic effects of GH remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574412     DOI: 10.2337/diabetes.50.10.2301

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  35 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.

Authors:  Kevin C Corbit; João Paulo G Camporez; Jennifer L Tran; Camella G Wilson; Dylan A Lowe; Sarah M Nordstrom; Kirthana Ganeshan; Rachel J Perry; Gerald I Shulman; Michael J Jurczak; Ethan J Weiss
Journal:  JCI Insight       Date:  2017-02-09

3.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

Review 4.  Effects of GH in human muscle and fat.

Authors:  Jens Otto Lunde Jørgensen; Kristine Z Rubeck; Thomas S Nielsen; Berthil F F Clasen; Mikkel Vendelboe; Thomas K Hafstrøm; Michael Madsen; Sten Lund
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

5.  Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.

Authors:  Burak Salgin; Maria L Marcovecchio; Rachel M Williams; Sarah J Jackson; Leslie J Bluck; Sandy M Humphreys; Carlo L Acerini; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

6.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

Review 7.  Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Yingxuan Wang; Guixia Wang
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

8.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

9.  Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Authors:  Takara L Stanley; Meghan N Feldpausch; Jinhee Oh; Karen L Branch; Hang Lee; Martin Torriani; Steven K Grinspoon
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

10.  The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.

Authors:  R M Williams; R Amin; F Shojaee-Moradie; A M Umpleby; C L Acerini; D B Dunger
Journal:  Diabetologia       Date:  2003-07-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.